Dianthus Therapeutics (NASDAQ:DNTH) Coverage Initiated by Analysts at JPMorgan Chase & Co.

Research analysts at JPMorgan Chase & Co. assumed coverage on shares of Dianthus Therapeutics (NASDAQ:DNTH) in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage set an “overweight” rating and a $135.00 price target on the stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 30.71% from the stock’s current price.

DNTH has been the topic of a number of other research reports. Guggenheim reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. TD Cowen restated a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Wolfe Research reaffirmed an “outperform” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Citigroup began coverage on shares of Dianthus Therapeutics in a research note on Friday, September 4th. They issued a “buy” rating and a $156.00 target price for the company. Finally, Wedbush increased their price objective on Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Dianthus Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $129.83.

Dianthus Therapeutics Stock Performance

DNTH stock opened at $103.28 on Friday. The business has a 50-day simple moving average of $106.23 and a two-hundred day simple moving average of $91.00. Dianthus Therapeutics has a 52-week low of $32.22 and a 52-week high of $117.88. The company has a market capitalization of $5.65 billion, a P/E ratio of -24.89 and a beta of 1.24.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.05). The firm had revenue of $0.76 million for the quarter, compared to the consensus estimate of $0.30 million. Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. As a group, sell-side analysts forecast that Dianthus Therapeutics will post -3.83 earnings per share for the current fiscal year.

Insider Transactions at Dianthus Therapeutics

In other Dianthus Therapeutics news, EVP Ryan Savitz sold 31,249 shares of Dianthus Therapeutics stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $101.03, for a total value of $3,157,086.47. Following the transaction, the executive vice president directly owned 31,249 shares of the company’s stock, valued at $3,157,086.47. The trade was a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Adam M. Veness sold 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $80.80, for a total value of $2,424,000.00. Following the completion of the sale, the senior vice president owned 30,000 shares of the company’s stock, valued at $2,424,000. The trade was a 50.00% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 283,678 shares of company stock valued at $29,672,400. 3.02% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in DNTH. Arizona State Retirement System grew its stake in shares of Dianthus Therapeutics by 5.7% in the second quarter. Arizona State Retirement System now owns 10,141 shares of the company’s stock worth $989,000 after purchasing an additional 546 shares during the last quarter. Nykredit A S purchased a new position in shares of Dianthus Therapeutics during the second quarter valued at approximately $147,000. Amundi bought a new stake in Dianthus Therapeutics in the second quarter worth $287,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Dianthus Therapeutics in the 2nd quarter worth about $1,033,000. Finally, California State Teachers Retirement System grew its position in Dianthus Therapeutics by 10,003.2% during the 2nd quarter. California State Teachers Retirement System now owns 4,100,301 shares of the company’s stock valued at $399,697,000 after purchasing an additional 4,059,717 shares during the last quarter. 47.53% of the stock is owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for complement-mediated diseases. The complement system is part of the immune system, and abnormal activation can contribute to autoimmune and inflammatory disorders. Dianthus is developing therapies designed to selectively inhibit complement activity while offering potentially durable treatment effects.

The company’s lead product candidate, DNTH103, is an investigational monoclonal antibody designed to inhibit C1s, a protein involved in the classical complement pathway.